> Detailanzeige

Flucke, Uta; Flucke, Maria Theresia; Hoy, Ludwig; Breuer, Elisabeth; Goebbels, Rolf; Rhiem, Kerstin; Schmutzler, Rita; Winzenried, Helene; Braun, Michael; Steiner, Susanne; Buettner, Reinhard; Gevensleben, Heidrun

Distinguishing medullary carcinoma of the breast from high‐grade hormone receptor‐negative invasive ductal carcinoma: an immunohistochemical approach

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Distinguishing medullary carcinoma of the breast from high‐grade hormone receptor‐negative invasive ductal carcinoma: an immunohistochemical approach
  • Beteiligte: Flucke, Uta; Flucke, Maria Theresia; Hoy, Ludwig; Breuer, Elisabeth; Goebbels, Rolf; Rhiem, Kerstin; Schmutzler, Rita; Winzenried, Helene; Braun, Michael; Steiner, Susanne; Buettner, Reinhard; Gevensleben, Heidrun
  • Erschienen: Wiley, 2010
  • Erschienen in: Histopathology
  • Sprache: Englisch
  • DOI: 10.1111/j.1365-2559.2010.03555.x
  • ISSN: 0309-0167; 1365-2559
  • Schlagwörter: General Medicine ; Histology ; Pathology and Forensic Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Flucke U, Flucke M T, Hoy L, Breuer E, Goebbels R, Rhiem K, Schmutzler R, Winzenried H, Braun M, Steiner S, Buettner R &amp; Gevensleben H
(2010) <jats:italic>Histopathology</jats:italic> <jats:bold>56,</jats:bold> 852–859
<jats:bold>Distinguishing medullary carcinoma of the breast from high‐grade hormone receptor‐negative invasive ductal carcinoma: an immunohistochemical approach</jats:bold></jats:p><jats:p><jats:bold>Aims: </jats:bold> Medullary carcinomas (MCs) represent a rare breast cancer subtype associated with a rather favourable prognosis compared with invasive ductal carcinomas (IDCs). Due to histopathological overlap, MCs are frequently misclassified as high‐grade IDCs, potentially leading to overtreatment of MCs. Our aim was to establish novel diagnostic markers distinguishing MCs from hormone receptor‐negative high‐grade IDCs.</jats:p><jats:p><jats:bold>Methods and results: </jats:bold> Sixty‐one MCs and 133 hormone receptor‐negative IDCs were analysed in a comparative immunohistochemical study. Applied markers included a comprehensive panel of cytokeratins (CKs), vimentin, smooth muscle actin (SMA), p63, p53, cell adhesion molecules [N‐CAM (CD56), syndecan‐1 (CD138), E‐cadherin and P‐cadherin] and development associated transcription factors (AP‐2α, AP‐2γ). A significantly higher proportion of IDCs displayed increased expression of CK7, AP‐2α and HER2 in contrast to MCs (CK7: 91% of IDCs versus 77% of MCs; AP‐2α: 77% versus 57%; and HER2: 26% versus 7%, each <jats:italic>P</jats:italic> &lt; 0.01). Vice versa, MCs were slightly more frequently positive for SMA and vimentin (<jats:italic>P</jats:italic> &gt; 0.05).</jats:p><jats:p><jats:bold>Conclusions: </jats:bold> Hormone receptor‐negative high‐grade IDCs are significantly associated with luminal differentiation, Her2 and AP‐2α overexpression, whereas MCs tend to display myoepithelial features. Markers analysed in this study are of diagnostic value regarding the differential diagnosis of MCs.</jats:p>